MedTrace Logo

A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects

NCT05868967 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-05-22

No results posted yet for this study

Summary

The purpose of this study is to investigate the Mass Balance and Biotransformation of \[14C\]DWP14012 in Healthy Chinese Male Subjects

Conditions

  • Phase 1 Study, Healthy Volunteers

Interventions

DRUG

[14C]DWP14012

Each subject will receive a single oral dose of \[14C\]DWP14012 suspension (containing approximately 40 mg/80 μCi \[14C\]DWP14012) under fasting conditions.

Sponsors & Collaborators

  • Shanghai Haini Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • Fang Hou · Beijing GoBroad Boren Hospital

  • Wel Tan · Beijing GoBroad Boren Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2023-05-31
Completion
2023-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05868967 on ClinicalTrials.gov